Table 2.

Grade 3 and 4 adverse events in patients who received therapy (n = 84)

Body system/category	Adverse event	No. patients (%)
		Grade 3	Grade 4
Hematologic	Anemia	2 (2)	0 (0)
	Leukopenia	41 (49)	8 (10)
	Lymphopenia	11 (13)	5 (6)
	Neutropenia	24 (29)	5 (6)
	Thrombocytopenia	9 (11)	0 (0)
Hemorrhage	Hemoptysis	1 (1)	0 (0)
Hepatic	Elevated ALT	2 (2)	1 (1)
	Elevated AST	3 (4)	1 (1)
	Elevated bilirubin	1 (1)	0 (0)
	Hypoalbuminemia	4 (5)	0 (0)
Infection	Febrile neutropenia	3 (4)	1 (1)
	Infection	4 (5)	0 (0)
Metabolic/laboratory	Hyperglycemia	8 (10)	0 (0)
	Hyperkalemia	1 (1)	0 (0)
	Hypocalcemia	7 (8)	3 (4)
	Hypokalemia	15 (18)	4 (5)
	Hypomagnesemia	8 (10)	2 (2)
	Hyponatremia	2 (2)	0 (0)
	Hypophosphatemia	2 (2)	0 (0)
	Elevated ALK phosphatase	1 (1)	0 (0)
Neurologic	Depression	1 (1)	0 (0)
	Neurosensory	1 (1)	0 (0)
	Syncope	2 (2)	0 (0)
Pain	Pain, abdominal	8 (10)	1 (1)
	Pain, back	1 (1)	0 (0)
	Pain, gingivitis	1 (1)	0 (0)
Renal/genitourinary	Polyuria	1 (1)	0 (0)
Cardiovascular	QTc interval prolongation	1 (1)	0 (0)
	Hypertension	1 (1)	0 (0)
	Hypotension	3 (4)	0 (0)
	Sinus bradycardia	1 (1)	0 (0)
	Thrombosis	2 (2)	1 (1)
Coagulation	Elevated PTT	1 (1)	0 (0)
	Elevated prothrombin time	2 (2)	0 (0)
Constitutional symptoms	Fatigue	14 (17)	0 (0)
	Weight loss	6 (7)	0 (0)
Dermatologic/skin	Alopecia	1 (1)	0 (0)
	Rash/desquamation	3 (4)	0 (0)
	RXN, hand/foot syndrome	9 (11)	0 (0)
	Pruritus	1 (1)	0 (0)
	Skin irritation	1 (1)	0 (0)
Gastrointestinal	Anorexia	22 (26)	1 (1)
	Dehydration	18 (21)	2 (2)
	Diarrhea	16 (19)	4 (5)
	Dysphagia	2 (2)	0 (0)
	Hemorrhoids	1 (1)	0 (0)
	Nausea	25 (30)	0 (0)
	Mucositis	19 (23)	1 (1)
	Vomiting	13 (15)	2 (2)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALK, alkaline; QTc, Q-T corrected; PTT, partial thromboplastin time; RXN, reaction.